ESTABLISHMENT LABS HOLDINGS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.98 USD | +2.03% |
|
+9.84% | +124.14% |
| 05-08 | Transcript : Establishment Labs Holdings Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| 05-08 | Establishment Labs Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +124.14% | 1.56B | B- | ||
| -4.71% | 182B | C+ | ||
| +0.70% | 110B | C | ||
| -3.68% | 67.92B | A | ||
| +4.10% | 50.96B | B- | ||
| +9.65% | 44.7B | B- | ||
| +2.70% | 40.66B | B+ | ||
| +18.85% | 27.6B | B | ||
| +4.54% | 26.63B | A- | ||
| +0.03% | 24.98B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ESTA Stock
- Ratings Establishment Labs Holdings Inc.